Phase Forward Signs 17 New Clintrial Customers in Past Year
Further expanding its global footprint in clinical data management (CDM), Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, has added 17 new organizations to its extensive roster of Clintrial(TM) customers in the past year. These new customers, which include U.S.-based ACCESS Medical, Nippon Shinyaku Co. of Japan, and the University of Poitiers in France, are utilizing the Clintrial solution to streamline paper-based clinical data entry and reduce the time and costs associated with their clinical trials. In addition to these customer wins, Phase Forward has also expanded its relationships in the past year with its large pharmaceutical, biotechnology, and contract research organizations (CRO) customers including Eli Lilly, Quintiles Transnational, and Schering Plough Research Institute.
Since its introduction in 1984, the world’s leading pharmaceutical, biotechnology, CRO, medical device, and academic institutions have been leveraging Phase Forward’s Clintrial system to streamline clinical trial data management. The company believes that its Clintrial product continues to win customers in the competitive clinical data management (CDM) market because of its ease of installation and set up and its open architecture that can be easily integrated with existing clinical systems – all of which contribute to a lower total cost of ownership.
Forenap-Pharma specializes in applied research in human pharmacology. “We selected Clintrial to manage the data in our clinical trial programs because of the speed and ease with which we could get the system up and running,” said Lilian Laborde, Head of Data Management, Forenap-Pharma. “Not only is Clintrial easy to deploy, but its easy-to-use interface minimizes the need for Oracle(R) database expertise and makes it simple to manage, maintain, and upgrade. The time saved in set-up and installation saves us money in the long run by enabling our trial staff to dedicate more time and resources to conducting trials for drug delivery.”
In addition to numerous pharmaceutical and biotechnology organizations, Clintrial has also been widely adopted by leading academic institutions. “Education and research are part of our core mission at Caritas St. Elizabeth’s Medical Center. Our research libraries are active centers of investigation where we are currently conducting numerous clinical trials in the areas of gene therapy, cell therapy, cardiology, neurology, hematology/oncology, pulmonary, and gastroenterology,” said Nicolaos Madias, M.D., chief academic officer, Caritas Christi Health Care, and chairman of medicine, Caritas St. Elizabeth’s Medical Center. “Phase Forward’s Clintrial system provides us with an excellent tool for managing our clinical trial data by providing us with real-time access and improved quality of data. As a result, we can ensure that the latest clinical information directs patient care.”
“The recent additions to our customer base demonstrate that organizations of all sizes, geographies, and disciplines are committing to Clintrial because of its ability to expedite the flow of clinical data and accelerate clinical research processes,” said Bob Weiler, president and CEO, Phase Forward. “Our increased penetration into international markets including Japan, the second largest country in the world in pharmaceutical R&D spending, exemplifies Phase Forward’s strong market presence and long-standing commitment to simplifying clinical data management.”
About Phase Forward
Phase Forward is a leading provider of integrated data management solutions for clinical trials and drug safety. The company helps pharmaceutical, biotechnology, and medical device companies bring needed drugs and therapies to market faster and more safely. Phase Forward offers proven solutions in electronic data capture (EDC), clinical data management (CDM), and adverse event reporting (AER). Phase Forward products and services have been utilized in over 10,000 clinical trials involving more than 1,000,000 clinical trial study participants at over 200 organizations worldwide including: AstraZeneca, Biogen Idec, Boston Scientific, Cedars-Sinai, Eli Lilly, GlaxoSmithKline, Guidant, Procter & Gamble, Quintiles, Sanofi-Aventis, and Schering-Plough Research Institute. Additional information about Phase Forward is available at www.phaseforward.com .
